Technical Analysis for GTHX - G1 Therapeutics, Inc.
|Grade||Last Price||% Change||Price Change|
GTHX closed down 4.05 percent on Monday, October 15, 2018, on approximately normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
|See historical GTHX trend table...|
|Date||Alert Name||Type||% Chg|
|Oct 15||Fell Below 200 DMA||Bearish||0.00%|
|Oct 15||Multiple of Ten Bullish||Other||0.00%|
|Oct 15||Wide Bands||Range Expansion||0.00%|
|Oct 15||Oversold Stochastic||Weakness||0.00%|
|Oct 12||Narrow Range Bar||Range Contraction||-4.05%|
|Oct 12||NR7||Range Contraction||-4.05%|
|Oct 12||Wide Bands||Range Expansion||-4.05%|
|Oct 12||Oversold Stochastic||Weakness||-4.05%|
|Oct 11||Wide Bands||Range Expansion||-4.09%|
|Oct 11||Oversold Stochastic||Weakness||-4.09%|
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
G1 Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6. Trilaciclib and G1T38 are designed to be combined and enhance the anti-tumor activity of current therapies. It is also developing G1T48, an oral selective estrogen receptor degrader (SERD) for the treatment of breast cancer. The Company is evaluating trilaciclib in three Phase II clinical trials. G1T38 is being evaluated in combination with Faslodex in a Phase I b/II a trial for patients with estrogen receptor-positive, HER2-negative breast cancer.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more GTHX news...
|52 Week High||69.57|
|52 Week Low||18.035|
|200-Day Moving Average||41.6236|
|50-Day Moving Average||55.8494|
|20-Day Moving Average||50.8635|
|10-Day Moving Average||44.799|
|Average True Range||3.1227|
|Chandelier Exit (Long, 3 ATRs )||59.0019|
|Chandelier Exit (Short, 3 ATRs )||49.2781|
|Upper Bollinger Band||64.5238|
|Lower Bollinger Band||37.2032|
|Percent B (%b)||0.15|
|MACD Signal Line||-3.4372|
|Market Cap||1.17 Billion|
|Num Shares||28.3 Million|
|Price-to-Earnings (P/E) Ratio||-3.74|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||45.47|
|Resistance 3 (R3)||45.50||44.11||44.77|
|Resistance 2 (R2)||44.11||43.04||44.10||44.53|
|Resistance 1 (R1)||42.68||42.37||41.99||42.65||44.29|
|Support 1 (S1)||39.86||40.22||39.17||39.83||38.19|
|Support 2 (S2)||38.47||39.55||38.46||37.95|
|Support 3 (S3)||37.04||38.47||37.72|
|Support 4 (S4)||37.01|